OKX to Adjust Discount Rates for BETH
NASSAU, the Bahamas, July 10, 2024 (GLOBE NEWSWIRE) -- OKX, a leading crypto exchange by trading volume and a leading Web3 technology company, has issued updates for July 11, 2024.
OKX to Adjust Discount Rates for BETH
OKX is announcing an adjustment to the discount rates for BETH in the multi-currency margin mode and portfolio margin mode. This adjustment is scheduled to take place on July 18, 2024, between 6:00 am and 8:00 am (UTC).
Following the adjustment, the discount rate for BETH will be higher. Importantly, this change will not affect the risk level of current positions held by users.
Specific Adjustments:
| Asset | Before | After | ||
| Tier (USD) | Discount rate | Tier (USD) | Discount rate | |
| BETH | 0 ~ 1,000,000 | 0.8 | 0 ~ 2,000,000 | 0.95 |
| 1,000,000 ~ 2,000,000 | 0.75 | 2,000,000 ~ 4,000,000 | 0.85 | |
| 2,000,000 ~ 4,000,000 | 0.5 | 4,000,000 ~ 8,000,000 | 0.5 | |
| > 4,000,000 | 0 | > 8,000,000 | 0 |
To learn more, visit OKX's Support Center.
For further information, please contact:
[email protected]
About OKX
OKX is a leading global crypto exchange and innovative Web3 company. Trusted by more than 50 million global users, OKX is known for being the fastest and most reliable crypto trading app for traders everywhere.
To learn more about OKX, download our app or visit: okx.com
Disclaimer
This announcement is provided for informational purposes only. It is not intended to provide any investment, tax, or legal advice, nor should it be considered an offer to purchase, sell, hold or offer any services relating to digital assets. Digital assets, including stablecoins, involve a high degree of risk, can fluctuate greatly, and can even become worthless.
Source: OKX
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Form 8.5 (EPT/RI)-Advanced Medical Solutions Group Plc
- Viasat demonstrates first integrated automotive satellite voice call capability with BMW Group
- Arletta Pharma Solutions Receives FDA Response Supporting the Clinical Development Program of Lybrido™ for Female Sexual Interest/Arousal Disorder in the US
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share